SK287794B6 - Laktámová zlúčenina, spôsob jej prípravy a použitie ako liečivo - Google Patents

Laktámová zlúčenina, spôsob jej prípravy a použitie ako liečivo Download PDF

Info

Publication number
SK287794B6
SK287794B6 SK543-2003A SK5432003A SK287794B6 SK 287794 B6 SK287794 B6 SK 287794B6 SK 5432003 A SK5432003 A SK 5432003A SK 287794 B6 SK287794 B6 SK 287794B6
Authority
SK
Slovakia
Prior art keywords
methyl
amino
benzazepin
tetrahydro
alaninyl
Prior art date
Application number
SK543-2003A
Other languages
English (en)
Slovak (sk)
Other versions
SK5432003A3 (en
Inventor
Thomas Mitchell Koenig
James Edmund Audia
David Mitchell
Stacey Leigh Mcdaniel
Lynne Ann Buccilli
Gary Lowell Engel
James Abraham Aikins
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of SK5432003A3 publication Critical patent/SK5432003A3/sk
Publication of SK287794B6 publication Critical patent/SK287794B6/sk

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D223/00Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16Benzazepines; Hydrogenated benzazepines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrrole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Cephalosporin Compounds (AREA)
SK543-2003A 2000-11-17 2001-11-02 Laktámová zlúčenina, spôsob jej prípravy a použitie ako liečivo SK287794B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24965600P 2000-11-17 2000-11-17
PCT/US2001/027795 WO2002040451A2 (fr) 2000-11-17 2001-11-02 Compose lactame

Publications (2)

Publication Number Publication Date
SK5432003A3 SK5432003A3 (en) 2004-09-08
SK287794B6 true SK287794B6 (sk) 2011-10-04

Family

ID=22944436

Family Applications (1)

Application Number Title Priority Date Filing Date
SK543-2003A SK287794B6 (sk) 2000-11-17 2001-11-02 Laktámová zlúčenina, spôsob jej prípravy a použitie ako liečivo

Country Status (33)

Country Link
US (1) US20040248878A1 (fr)
EP (1) EP1353910B1 (fr)
JP (1) JP4116431B2 (fr)
KR (1) KR20030045194A (fr)
CN (2) CN100516047C (fr)
AR (1) AR031356A1 (fr)
AT (1) ATE362919T1 (fr)
AU (2) AU2002224321B2 (fr)
BR (1) BR0115424A (fr)
CA (1) CA2425497C (fr)
CY (1) CY1106682T1 (fr)
CZ (1) CZ20031340A3 (fr)
DE (1) DE60128587T2 (fr)
DK (1) DK1353910T3 (fr)
DZ (1) DZ3454A1 (fr)
EA (1) EA006919B1 (fr)
EC (1) ECSP034598A (fr)
ES (1) ES2286162T3 (fr)
HR (1) HRP20030385A2 (fr)
HU (1) HUP0301862A3 (fr)
IL (1) IL155275A0 (fr)
MX (1) MXPA03004250A (fr)
MY (1) MY141607A (fr)
NO (1) NO325217B1 (fr)
PE (1) PE20020798A1 (fr)
PL (1) PL211018B1 (fr)
PT (1) PT1353910E (fr)
SK (1) SK287794B6 (fr)
SV (1) SV2003000741A (fr)
TW (1) TWI235151B (fr)
UA (1) UA77165C2 (fr)
WO (1) WO2002040451A2 (fr)
ZA (1) ZA200303411B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
ES2401216T3 (es) 2002-12-20 2013-04-17 Glaxo Group Limited Nuevos derivados de benzazepina
ATE374766T1 (de) 2003-01-14 2007-10-15 Arena Pharm Inc 1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
EP1867636B1 (fr) 2005-04-08 2013-06-05 Daiichi Sankyo Company, Limited Dérivé de pyridylméthylsulfone
EP1985615A4 (fr) 2006-01-31 2011-12-14 Api Corp Procédé de production de benzazépinone
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
FR2932800B1 (fr) * 2008-06-20 2015-02-20 Servier Lab Nouveau procede de synthese de la 7,8-dimethoxy-1,3-dihydro- 2h-3-benzazepin-2-one, et application a la synthese de l'ivabradine et de ses sels d'addition a un acide pharmaceutiquement acceptable
CA2812061A1 (fr) 2010-09-22 2012-03-29 Arena Pharmaceuticals, Inc. Modulateurs du recepteur gpr119 et traitement des troubles qui lui sont lies
KR101899014B1 (ko) 2012-01-06 2018-09-17 삼성전자주식회사 비엘디씨 모터의 제어 장치 및 그 방법
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
US20160067306A1 (en) 2013-04-19 2016-03-10 National University Corporation Hokkaido University Treatment agent for cognitive impairment induced by amyloid beta-protein, therapeutic agent for alzheimer's disease, and treatment method and pathological analysis method related to these
CN107405332A (zh) 2015-01-06 2017-11-28 艾尼纳制药公司 治疗与s1p1受体有关的病症的方法
CA3002551A1 (fr) 2015-06-22 2016-12-29 Arena Pharmaceuticals, Inc. Sel cristallin de l-arginine de (r)(7-(4-cyclopentyle-3-(trifluoromethyle)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta[b]indol-3-yl)acide acetique(compose 1) aux fins d'utilisation contre les troubles associes au recepteur s1p1
CN110520124A (zh) 2017-02-16 2019-11-29 艾尼纳制药公司 用于治疗原发性胆汁性胆管炎的化合物和方法
WO2021195362A1 (fr) 2020-03-26 2021-09-30 Seagen Inc. Méthodes de traitement du myélome multiple

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA002100B1 (ru) * 1996-12-23 2001-12-24 Элан Фармасьютикалз, Инк. ЦИКЛОАЛКИЛЬНЫЕ СОЕДИНЕНИЯ, ЛАКТАМЫ, ЛАКТОНЫ И РОДСТВЕННЫЕ СОЕДИНЕНИЯ, СОДЕРЖАЩИЕ ИХ ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ВЫСВОБОЖДЕНИЯ И/ИЛИ СИНТЕЗА β-АМИЛОИДНОГО ПЕПТИДА С ПОМОЩЬЮ УКАЗАННЫХ СОЕДИНЕНИЙ
WO1999067219A1 (fr) * 1998-06-22 1999-12-29 Elan Pharmaceuticals, Inc. Composes destines a inhiber la liberation et/ou la synthese du peptide beta-amyloide
EP1230220A1 (fr) * 1999-11-09 2002-08-14 Eli Lilly And Company COMPOSES CONTENANT DES $g(b)-ACIDES AMINES UTILES POUR INHIBER LA LIBERATION ET/OU LA SYNTHESE DU PEPTIDE $g(b)-AMYLOIDE

Also Published As

Publication number Publication date
MXPA03004250A (es) 2003-09-22
CZ20031340A3 (cs) 2004-06-16
EA200300579A1 (ru) 2003-12-25
HUP0301862A2 (hu) 2003-09-29
CA2425497C (fr) 2010-08-17
UA77165C2 (en) 2006-11-15
CN100516047C (zh) 2009-07-22
NO325217B1 (no) 2008-02-25
DE60128587D1 (de) 2007-07-05
DE60128587T2 (de) 2008-01-31
NO20032215D0 (no) 2003-05-15
SV2003000741A (es) 2003-01-13
HRP20030385A2 (en) 2003-08-31
NO20032215L (no) 2003-07-16
AR031356A1 (es) 2003-09-17
PL360991A1 (en) 2004-09-20
AU2002224321B2 (en) 2006-10-19
BR0115424A (pt) 2003-10-21
CN1575282A (zh) 2005-02-02
PE20020798A1 (es) 2002-09-06
IL155275A0 (en) 2003-11-23
WO2002040451A2 (fr) 2002-05-23
ZA200303411B (en) 2004-08-02
US20040248878A1 (en) 2004-12-09
DZ3454A1 (fr) 2002-05-23
CY1106682T1 (el) 2012-05-23
CN101624372A (zh) 2010-01-13
CA2425497A1 (fr) 2002-05-23
MY141607A (en) 2010-05-31
PT1353910E (pt) 2007-08-20
TWI235151B (en) 2005-07-01
ATE362919T1 (de) 2007-06-15
KR20030045194A (ko) 2003-06-09
AU2432102A (en) 2002-05-27
HUP0301862A3 (en) 2007-09-28
SK5432003A3 (en) 2004-09-08
EP1353910A2 (fr) 2003-10-22
ECSP034598A (es) 2003-06-25
JP2004521084A (ja) 2004-07-15
WO2002040451A3 (fr) 2003-08-28
DK1353910T3 (da) 2007-09-10
JP4116431B2 (ja) 2008-07-09
ES2286162T3 (es) 2007-12-01
PL211018B1 (pl) 2012-03-30
EA006919B1 (ru) 2006-04-28
EP1353910B1 (fr) 2007-05-23

Similar Documents

Publication Publication Date Title
CA2427227C (fr) Compose de lactam
US7468365B2 (en) Lactam compound
AU2002243192A1 (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
JP4116431B2 (ja) ラクタム化合物
JP2004521084A5 (fr)
AU2002224321A1 (en) Lactam compound
EP1345955B1 (fr) Dipeptide de lactame utile pour inhiber la liberation du peptide beta-amyloide
CA2390376A1 (fr) Composes contenant des .beta.-acides amines utiles pour inhiber la liberation et/ou la synthese du peptide .beta.-amyloide
US20040077627A1 (en) Lactam compound
CA2388750A1 (fr) Composes contenant des .beta.-acides amines utiles pour inhiber la liberation et/ou la synthese du peptide .beta.-amyloide
NZ525365A (en) Lactam compound

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20141102